Zhejiang Shouxian Valley Pharmaceutical Joint-Stock Co., Ltd. Announcement on the Addition of Certified Public Accountants

robot
Abstract generation in progress

Security Code: 603896 | Stock Short Name: Shouxiangu | Announcement No.: 2026-004

Bond Code: 113660 | Bond Short Name: Shou 22 Convertible Bond

Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

Announcement on Adding a Signed Registered Public Accountant

The board of directors of the Company and all its directors hereby warrant that this announcement contains no false records, misleading statements, or material omissions, and will assume individual and joint liability for the truthfulness, accuracy, and completeness of the contents of this announcement.

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) convened the 28th meeting of the fourth session of the board of directors on April 17, 2025. The meeting deliberated and approved the proposal on “Reappointing the Company’s Audit Firm for FY2025,” and agreed to continue appointing the accounting firm of BDO China Shuoyang Certified Public Accountants (Special General Partnership) (hereinafter referred to as “BDO Shuoyang”) as the Company’s audit firm for FY2025. BDO Shuoyang will be responsible for the audit of the Company’s financial statements, the audit of internal controls, and other related audit work. For details, please refer to the Company’s announcement titled “Announcement on Reappointing the Accounting Firm” published on April 18, 2025 on the website of the Shanghai Stock Exchange (www.see.com.cn) (Announcement No.: 2025-020).

Recently, the Company received from BDO Shuoyang a letter titled “Letter on the Addition of a Signed Registered Public Accountant for the Audit Firm of Zhejiang Shouxiangu Pharmaceutical Co., Ltd.” The relevant matters are hereby announced as follows:

I. Circumstances Concerning the Addition of the Signed Registered Public Accountant in This Instance

As the audit firm for the Company’s FY2025 financial statement audit, BDO Shuoyang originally assigned Zhu Zuowu as the project partner and signed registered public accountant, and Lü Qi as the signed registered public accountant, to provide audit services to the Company. Now, due to internal work arrangements of BDO Shuoyang, it has added Liu Qiaowei as the signed registered public accountant. After this adjustment, Zhu Zuowu will continue to serve as the project partner and signed registered public accountant, while Liu Qiaowei and Lü Qi will serve as the signed registered public accountants, to further complete the Company’s FY2025 audit-related work.

II. Relevant Information on the Signed Registered Public Accountant Added in This Instance

  1. Basic Information

Liu Qiaowei has been engaged in the audit work for listed companies since 2014. In 2019, she/he became a practicing certified public accountant. Liu Qiaowei has been practicing at BDO Shuoyang since 2014 and has professional competence to perform the duties. In the past three years, there were 0 listed company audit reports signed.

  1. Independence and Integrity of the Signed Registered Public Accountant Added in This Instance

Liu Qiaowei has no circumstances that violate the requirements for independence set forth in the “Code of Professional Ethics for Chinese Certified Public Accountants,” and has not been subject to any criminal punishment, administrative penalty, administrative regulatory measures, or self-disciplinary actions in the past three years. This complies with the provisions on regular rotation, and there is no record of poor integrity.

This adjustment will not have any adverse impact on the Company’s FY2025 audit work.

III. Documents for Reference

BDO Shuoyang’s “Letter on the Addition of a Signed Registered Public Accountant for the Audit Firm of Zhejiang Shouxiangu Pharmaceutical Co., Ltd.”

This announcement is hereby issued.

Board of Directors of Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

April 1, 2026

Endless information and precise interpretation—available in the Sina Finance APP

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments